BioSpace News Archive

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2021 and provided full year 2022 financial guidance.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB).

CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full year ended December 31, 2021.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the first participant has been dosed in the Phase 2 study of the Company’s Omicron-specific booster candidate.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced that an IND application to initiate the first clinical trial in China for 3D189, also known as SELLAS’ galinpepimut-S, has been accepted by China’s National Medical Products Administration.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced the pricing of its underwritten public offering of 9,160,000 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,340,000 common shares.

Sierra Oncology, Inc. announced the pricing of an upsized underwritten public offering of 4,074,075 shares of its common stock and, in lieu of shares of common stock, to a certain investor, pre-funded warrants to purchase up to 925,925 shares of common stock pursuant to its existing shelf registration statement.

Hillstream BioPharma, Inc. today announced a collaboration with University of Massachusetts Chan Medical School to determine the chemogenetic interactions of HSB-1216.

Evolus, Inc. today announced its preliminary, unaudited net revenue and cash position as of and for the fourth quarter and full-year ended December 31, 2021.

Checkpoint Surgical, Inc., the leader in intraoperative nerve repair stimulation technology, today announced it has enrolled the first patient in its multi-center clinical study of the company’s breakthrough nerve regeneration technology.